Table 1 Adverse outcomes in SMART study18 in relation to inhaled corticosteroid (ICS) use
SalmeterolPlaceboRR (95% CI)
Combined respiratory related death or life threatening episode*
    Baseline ICS use23191.21 (0.66 to 2.23)
    No baseline ICS use27171.60 (0.87 to 2.92)
Asthma deaths†
    Baseline ICS use431.35 (0.30 to 6.04)
    No baseline ICS use90
  • *Primary outcome variable; ‡secondary outcome variable.

  • RR, relative risk.